Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers

The flavanol epigallocatechin gallate (EGCG) is being tested for the treatment of several diseases in humans. However, its bioavailability and pharmacokinetic profile needs a better understanding to enable its use in clinical trials. There is no consensus on the most appropriate concentration of EGC...

ver descrição completa

Detalhes bibliográficos
Autores: Andreu Fernández, Vicente, Almeida Toledano, Laura, Pizarro Lozano, Ma. Nieves, Navarro-Tapia, Elisabet, Gómez Roig, Ma. Dolores, Torre Fornell, Rafael de la, García-Algar, Oscar
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2020
País:España
Recursos:Universitat Pompeu Fabra
Repositório:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/45467
Acesso em linha:http://hdl.handle.net/10230/45467
http://dx.doi.org/10.3390/antiox9050440
Access Level:Acceso aberto
Palavra-chave:EGCG
Epigallocatechin Gallate
Teavigo®
Bioavailability
Antioxidants
Catechins
Food supplement
Green tea
Pharmacokinetic profile
Polyphenols
id ES_89e8a17b74a25d66318c2f3473bef8fd
oai_identifier_str oai:repositori.upf.edu:10230/45467
network_acronym_str ES
network_name_str España
repository_id_str
spelling Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteersAndreu Fernández, VicenteAlmeida Toledano, LauraPizarro Lozano, Ma. NievesNavarro-Tapia, ElisabetGómez Roig, Ma. DoloresTorre Fornell, Rafael de laGarcía-Algar, OscarEGCGEpigallocatechin GallateTeavigo®BioavailabilityAntioxidantsCatechinsFood supplementGreen teaPharmacokinetic profilePolyphenolsThe flavanol epigallocatechin gallate (EGCG) is being tested for the treatment of several diseases in humans. However, its bioavailability and pharmacokinetic profile needs a better understanding to enable its use in clinical trials. There is no consensus on the most appropriate concentration of EGCG in the body to obtain the maximum therapeutic effects. Therefore, the aim of this study is to analyze the bioavailability of EGCG orally administered alone or with different food supplements after overnight fasting in order to determine its optimal conditions (high concentrations in blood and the lowest interindividual variations) to be used as a pharmacological tool in human trials. Ten healthy volunteers (5 men and 5 women) aged 25 to 35 years were recruited prospectively. Three series of clinical experiments with a washout period of seven days among each were performed: 1) Teavigo® (EGCG extract) alone, 2) Teavigo® with a standard breakfast, and 3) FontUp® (Teavigo® commercially prepared with fats, carbohydrates, proteins, vitamins, and minerals). Blood samples were collected at 0, 30, 60, 90, 120, 180, 240, and 360 min after EGCG intake. Free EGCG in plasma was measured using a liquid chromatography and mass spectrometry UPLC-ESI-MS/MS analytical method. The pharmacokinetic variables analyzed statistically were area under the curve (AUC0-360), Cmax, Cav, Cmin, T1/2, and Tmax,. EGCG (Teavigo®) alone was the group with higher AUC0-360, Cmax, and Cav both in men (3.86 ± 4.11 µg/mL/kg/6 h; 5.95 ng/mL/kg; 2.96 ng/mL/kg) and women (3.33 ± 1.08 µg/mL/kg/6 h; 6.66 ng/mL/kg; 3.66 ng/mL). Moreover, FontUp® was the group with the highest value of T1/2 both in men (192 ± 66 min) and women (133 ± 28 min). Teavigo® intake after fasting overnight revealed the highest concentration of EGCG in plasma according to its pharmacokinetic profile, indicating that this is an excellent alternative of administration if the experimental design requires good absorption in the gastrointestinal tract. Moreover, EGCG taken along with food supplements (FontUp®) improved the stability of the molecule in the body, being the best choice if the experimental design wants to reduce interindividual variation.MDPI202020202020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/45467http://dx.doi.org/10.3390/antiox9050440reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésAntioxidants (Basel). 2020 May 19;9(5):440Copyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/454672026-06-12T07:21:37Z
dc.title.none.fl_str_mv Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers
title Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers
spellingShingle Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers
Andreu Fernández, Vicente
EGCG
Epigallocatechin Gallate
Teavigo®
Bioavailability
Antioxidants
Catechins
Food supplement
Green tea
Pharmacokinetic profile
Polyphenols
title_short Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers
title_full Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers
title_fullStr Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers
title_full_unstemmed Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers
title_sort Bioavailability of epigallocatechin gallate administered with different nutritional strategies in healthy volunteers
dc.creator.none.fl_str_mv Andreu Fernández, Vicente
Almeida Toledano, Laura
Pizarro Lozano, Ma. Nieves
Navarro-Tapia, Elisabet
Gómez Roig, Ma. Dolores
Torre Fornell, Rafael de la
García-Algar, Oscar
author Andreu Fernández, Vicente
author_facet Andreu Fernández, Vicente
Almeida Toledano, Laura
Pizarro Lozano, Ma. Nieves
Navarro-Tapia, Elisabet
Gómez Roig, Ma. Dolores
Torre Fornell, Rafael de la
García-Algar, Oscar
author_role author
author2 Almeida Toledano, Laura
Pizarro Lozano, Ma. Nieves
Navarro-Tapia, Elisabet
Gómez Roig, Ma. Dolores
Torre Fornell, Rafael de la
García-Algar, Oscar
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv EGCG
Epigallocatechin Gallate
Teavigo®
Bioavailability
Antioxidants
Catechins
Food supplement
Green tea
Pharmacokinetic profile
Polyphenols
topic EGCG
Epigallocatechin Gallate
Teavigo®
Bioavailability
Antioxidants
Catechins
Food supplement
Green tea
Pharmacokinetic profile
Polyphenols
description The flavanol epigallocatechin gallate (EGCG) is being tested for the treatment of several diseases in humans. However, its bioavailability and pharmacokinetic profile needs a better understanding to enable its use in clinical trials. There is no consensus on the most appropriate concentration of EGCG in the body to obtain the maximum therapeutic effects. Therefore, the aim of this study is to analyze the bioavailability of EGCG orally administered alone or with different food supplements after overnight fasting in order to determine its optimal conditions (high concentrations in blood and the lowest interindividual variations) to be used as a pharmacological tool in human trials. Ten healthy volunteers (5 men and 5 women) aged 25 to 35 years were recruited prospectively. Three series of clinical experiments with a washout period of seven days among each were performed: 1) Teavigo® (EGCG extract) alone, 2) Teavigo® with a standard breakfast, and 3) FontUp® (Teavigo® commercially prepared with fats, carbohydrates, proteins, vitamins, and minerals). Blood samples were collected at 0, 30, 60, 90, 120, 180, 240, and 360 min after EGCG intake. Free EGCG in plasma was measured using a liquid chromatography and mass spectrometry UPLC-ESI-MS/MS analytical method. The pharmacokinetic variables analyzed statistically were area under the curve (AUC0-360), Cmax, Cav, Cmin, T1/2, and Tmax,. EGCG (Teavigo®) alone was the group with higher AUC0-360, Cmax, and Cav both in men (3.86 ± 4.11 µg/mL/kg/6 h; 5.95 ng/mL/kg; 2.96 ng/mL/kg) and women (3.33 ± 1.08 µg/mL/kg/6 h; 6.66 ng/mL/kg; 3.66 ng/mL). Moreover, FontUp® was the group with the highest value of T1/2 both in men (192 ± 66 min) and women (133 ± 28 min). Teavigo® intake after fasting overnight revealed the highest concentration of EGCG in plasma according to its pharmacokinetic profile, indicating that this is an excellent alternative of administration if the experimental design requires good absorption in the gastrointestinal tract. Moreover, EGCG taken along with food supplements (FontUp®) improved the stability of the molecule in the body, being the best choice if the experimental design wants to reduce interindividual variation.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/45467
http://dx.doi.org/10.3390/antiox9050440
url http://hdl.handle.net/10230/45467
http://dx.doi.org/10.3390/antiox9050440
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Antioxidants (Basel). 2020 May 19;9(5):440
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412662082797568
score 15,81155

Registros relacionados